Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

OREX 5.89 -0.09 (-1.55%)
price chart
Why Orexigen Therapeutics, Inc. Stock Rocketed 43% Higher in November
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing drugs to treat obesity, put on some serious heft and gained 43% during the month of November, data courtesy of S&P Capital IQ, after reporting ...
Stock Insight: Orexigen Therapeutics, Inc. (NASDAQ:OREX)  Markets Wired
Company High Short Interest: Orexigen Therapeutics , Cree Inc  Markets Insider
Related articles »  
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
What: Shares of Orexigen Therapeutics (NASDAQ: OREX ) , a biopharmaceutical company focused on developing therapies to treat obesity, surged higher by as much as 33% after the company reported its third-quarter earnings results and provided an ...
Orexigen (OREX) Up On Strong Q3 Results  Bidness ETC
Orexigen Therapeutics rises as European Union review of weight loss drug ...  Fox Business
Related articles »  
Stock Insight: Orexigen Therapeutics Inc. (NASDAQ:OREX)
[PRNewswire] Orexigen Therapeutics, Inc. (NASDAQ:OREX) (TREND ANALYSIS) announced that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the ...
Morning Movers: JUNO THERAPEUTICS, INC. (JUNO), Orexigen Therapeutics ...  WallStreet Scope
Related articles »  
How Bad Is This Delay for Orexigen Therapeutics, Inc?
Orexigen Therapeutics (NASDAQ: OREX ) recently announced that the Food and Drug Administration was delaying an approval decision on the biotech's obesity drug Contrave for three months.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
In 2011, Orexigen was in a tight race with VIVUS (NASDAQ: VVUS ) and Arena Pharmaceuticals (NASDAQ: ARNA ) to gain FDA approval of the first new obesity drug.
Orexigen Wins US FDA Approval for Weight-Loss Pill  Businessweek
Takeda and Orexigen Announce FDA Approval of Contrave´┐Ż (naltrexone HCI ...  MarketWatch
Related articles »  
Orexigen - Contrave Script Numbers Remain Impressive
Orexigen's (NASDAQ:OREX) anti-obesity drug Contrave seems to have found a sales groove that eluded competitors Vivus (NASDAQ:VVUS) and Arena (NASDAQ:ARNA).
Stock in Focus: Orexigen Therapeutics Inc. (NASDAQ:OREX)  Stock Markets Daily
Orexigen's Obesity Drug Mysimba Gets CHMP Nod  Zacks.com
Related articles »  
Orexigen Therapeutics, Inc. (OREX) Bulls Wager On Sharp Gains
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has surged 3.8% to trade at $5.96, and calls are flying off the shelves at almost nine times the expected intraday clip.
Not Even a Weight Loss Drug Could Stop Orexigen Therapeutics, Inc. From ...
Those fears have sparked a flurry of research and development into drugs that could help reduce the risk of type 2 diabetes by helping patients lose weight, including Orexigen Therapeutics' (NASDAQ: OREX ) recently approved Contrave. Yet despite ...
Related articles »  
Orexigen Therapeutics (OREX) Moving On Heavy Pre-Market Trading
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
Buzz Stocks: Nike Inc, Orexigen Therapeutics, Inc., and Xerox Corp  Schaeffers Research (blog)
Mid Day Movers: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Cerus ...  Market News Call
Related articles »  
Morning Buzz: ImmunoGen (IMGN), Cerus Corporation (CERS), BlackBerry ...
Orexigen Therapeutics, Inc. (OREX) shares are higher by 6.40% on heavy volume in midday trading on Friday, after the company confirms that the Committee for Medicinal Products For Human Use of the European Medicines Agency has adopted a positive ...
Related articles »